Basic Information:
Name:
Purevax RCP Lyophilisate and solvent for suspension for injection.
Composition:
One 1 ml or 0.5 ml dose contains:
Lyophilisate: Active ingredients: Attenuated feline rhinotracheitis virus (herpesvirus strain FHV F2) ≥ 104.9 TCID50 (tissue culture infectious dose 50%), Inactivated feline calicivirus antigens (strains FCV 431 and G1) ≥ 2.0 ELISA e.g., Attenuated feline panleukopenia virus (strain PLI IV) ≥ 103.5 TCID50. Other ingredient: Gentamicin, max. 16.5 µg
Solvent: Water for injections q.s. 1 ml or 0.5 ml
Indications:
Active immunization of cats from 8 weeks of age:
- against feline rhinotracheitis (herpesvirus infection) to reduce clinical symptoms,
- against calicivirus infection to reduce clinical symptoms,
- against feline panleukopenia to prevent mortality and clinical symptoms.
Onset of immunity: 1 week after primary vaccination.
Duration of immunity: 1 year after primary vaccination and 3 years after the last booster vaccination.
Contraindications:
None.
Adverse reactions: Temporary lethargy and loss of appetite, as well as elevated body temperature (usually lasting 1 to 2 days), were frequently observed during safety and field studies. A local reaction (mild pain on palpation, itching, or localized swelling), which usually resolves within 1 or at most 2 weeks, was frequently observed during safety and field studies.
Vomiting (usually within 24 to 48 hours) has been observed in very rare cases, based on post-marketing tolerability data.
Hypersensitivity reactions have occasionally been observed in field studies. They may require appropriate symptomatic treatment.
Pharmaceutical company:
Boehringer Ingelheim Vetmedica GmbH